Tags

Type your tag names separated by a space and hit enter

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
bioRxiv. 2021 Feb 22B

Abstract

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Preprint

Language

eng

PubMed ID

33655254

Citation

Edara, Venkata Viswanadh, et al. "Reduced Binding and Neutralization of Infection- and Vaccine-induced Antibodies to the B.1.351 (South African) SARS-CoV-2 Variant." BioRxiv : the Preprint Server for Biology, 2021.
Edara VV, Norwood C, Floyd K, et al. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv. 2021.
Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., Patel, S., Byram, R., Gomes, D. N., Michael, G., Abdullahi, H., Beydoun, N., Panganiban, B., McNair, N., Hellmeister, K., ... Suthar, M. S. (2021). Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2021.02.20.432046
Edara VV, et al. Reduced Binding and Neutralization of Infection- and Vaccine-induced Antibodies to the B.1.351 (South African) SARS-CoV-2 Variant. bioRxiv. 2021 Feb 22; PubMed PMID: 33655254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. AU - Edara,Venkata Viswanadh, AU - Norwood,Carson, AU - Floyd,Katharine, AU - Lai,Lilin, AU - Davis-Gardner,Meredith E, AU - Hudson,William H, AU - Mantus,Grace, AU - Nyhoff,Lindsay E, AU - Adelman,Max W, AU - Fineman,Rebecca, AU - Patel,Shivan, AU - Byram,Rebecca, AU - Gomes,Dumingu Nipuni, AU - Michael,Garett, AU - Abdullahi,Hayatu, AU - Beydoun,Nour, AU - Panganiban,Bernadine, AU - McNair,Nina, AU - Hellmeister,Kieffer, AU - Pitts,Jamila, AU - Winters,Joy, AU - Kleinhenz,Jennifer, AU - Usher,Jacob, AU - O'Keefe,James B, AU - Piantadosi,Anne, AU - Waggoner,Jesse J, AU - Babiker,Ahmed, AU - Stephens,David S, AU - Anderson,Evan J, AU - Edupuganti,Srilatha, AU - Rouphael,Nadine, AU - Ahmed,Rafi, AU - Wrammert,Jens, AU - Suthar,Mehul S, Y1 - 2021/02/22/ PY - 2021/3/3/entrez PY - 2021/3/4/pubmed PY - 2021/3/4/medline JF - bioRxiv : the preprint server for biology JO - bioRxiv N2 - The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19. UR - https://www.unboundmedicine.com/medline/citation/33655254/Reduced_binding_and_neutralization_of_infection__and_vaccine_induced_antibodies_to_the_B_1_351__South_African__SARS_CoV_2_variant_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.